Halozyme Therapeutics, Inc. (HALO)

66.65 -1.40 (-2.06%) USD  |  NASDAQ  |  Apr 16, 16:00
66.74 +0.09 (+0.14%) After-Hours: 19:35
More

Halozyme Therapeutics Research and Development Expense (Quarterly) : 31.90M for Dec. 31, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for HALO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Johnson & Johnson 4.268B
Eli Lilly & Co. 3.802B
Vertex Pharmaceuticals, Inc. 973.70M
Glaukos Corp. 43.65M
Agenus, Inc. 7.511M